Blood | American Society of Hematology

Skip Nav Destination

Current Issue

Volume 145,

Issue 7,

February 13 2025

View This Issue

Issue Highlights

CD70- and CD33-targeted CAR T cells in AML
Review Series: mantle cell lymphoma
Three-year follow-up of mosunetuzumab in refractory follicular lymphoma
Heme promotes venetoclax resistance in multiple myeloma
Resistance to BET inhibition in AML
RBC storage lesion as a ferroptotic process

Latest in Blood

Free Articles

Nonleukemic T/B mixed phenotype acute leukemia with PHF6 and NOTCH1 mutations

Oscar Silva; Allison Shaw

https://doi.org/10.1182/blood.2021012538

View All Free Articles

Plenary Papers

Genetic iron overload aggravates, and pharmacological iron restriction improves, MDS pathophysiology in a preclinical study

Ada Antypiuk; S. Zebulon Vance; Richa Sharma; Sara Passos; Michela Asperti; Shobana Navaneethabalakrishan; Franz Dürrenberger; Vania Manolova; Francesca Vinchi

https://doi.org/10.1182/blood.2024026135

View All Plenary Papers

First Edition

Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12)

Julio C. Chavez; Michael Dickinson; Javier Munoz; Matthew L. Ulrickson; Catherine Thieblemont; Olalekan O. Oluwole; Alex F. Herrera; Chaitra Ujjani; Yi Lin; Peter A. Riedell; Natasha Kekre; Sven de Vos; Jacob Wullf; Chad M. Williams; Joshua Winters; Ioana Magdalena Kloos, Dr; Hairong Xu; Sattva S. Neelapu

https://doi.org/10.1182/blood.2024027347

View All First Edition Articles

Clinical Trials and Observations

Treatment of relapsed/refractory MCL

Elisabeth Silkenstedt; Martin Dreyling

https://doi.org/10.1182/blood.2023022353

View All Clinical Trials and Observations

Advertisement intended for health care professionals

170,000 citations
earned in 2023

ASH Clinical News Seeks Its Next Editor-in-Chief
2024 Blood Cover Art Contest Winner
Year in review: Blood's ten most read articles published in 2024
Acknowledgement of Reviewers

Featured Content

Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells

Issue Highlights

170,000 citations
earned in 2023

Featured Content

Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation

Ferroptosis regulates hemolysis in stored murine and human red blood cells

ASH Publications

American Society of Hematology

Issue Highlights

170,000 citations earned in 2023

Featured Content

Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation

Ferroptosis regulates hemolysis in stored murine and human red blood cells

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

170,000 citations
earned in 2023